PIII P3 Health Partners (PIII) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-health services · CIK 0001832511
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
12
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · no price filed
What the filings say about PIII
Insiders, 180 days
-$823.9K net sold
1 seller · 0% of sales under a 10b5-1 plan
P3 Health Partners insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, P3 Health Partners Inc. insiders sold a net $823.9K of stock across 53 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 2.1% of the 48,959 shares held after it.
- No other insider sold within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Hudson Vegas Investment SPV, LLC sold about $13.9K of PIII on Aug 10, 2026, the largest insider sale at the company on our record; 12 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 63.8% of the 29,885 shares held after it.
- No other insider sold within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Hudson Vegas Investment SPV, LLC sold about $306.1K of PIII on Aug 10, 2026, the largest insider sale at the company on our record; 12 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- No other insider sold within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Hudson Vegas Investment SPV, LLC sold about $503.9K of PIII on Aug 10, 2026, the largest insider sale at the company on our record; 12 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Sep 12, 2024.
- -40.7% median (-37.4% mean) 90-day return after 6 previous buys.
- The trade is 0.1% of the 77,185,438 shares held after it.
- 2 other insiders bought within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider CPF III-A PT SPV, LLC bought about $40.0K of PIII on Sep 13, 2024; 2 other insiders bought within 30 days and 12 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Sep 11, 2023.
- -38.9% median (-33.7% mean) 90-day return after 5 previous buys.
- The trade is 0.1% of the 77,105,438 shares held after it.
- 2 other insiders bought within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider CPF III-A PT SPV, LLC bought about $41.6K of PIII on Sep 12, 2024; 2 other insiders bought within 30 days and 12 funds added in the latest 13F quarter.53 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$823.9K over 180 days
-$823.9K over 90 days · -$823.9K of it by a 10%+ holder
more than 56% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
12 funds bought in last quarter
below 90% of Healthcare Services
Revenue
-2.8% year over year
below 83% of Healthcare Services
Margin
-10.1% net margin
below 72% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
0.6% of the float short (float per yahoo 2026-10-26) · 1.4 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PIII
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-56.3%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PIII: institutional holders (13F)
13F holdings, latest reported quarter
54,495 sh
$588.5K
41,484 sh
$448.0K
33,540 sh
$362.2K
20,000 sh
$216.0K
19,737 sh
$213.2K
Congress trades in PIII
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PIII planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
PIII mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$106.1K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$140.1K position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$39.1K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$7.4K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$29.7K position · as of 2026-05-31
0.0%
Knights of Columbus U.S. ALL CAP INDEX FUND
$80 position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $823.9K sold by insiders over 180 days, 12 funds added last quarter. Each figure is a federal filing, dated the day it went public.
PIII financials
Revenue growth
-2.8%
XBRL, annual
Net margin
-10.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.5B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PIII
| FY Dec 2025 | $1.5B |
| FY Dec 2024 | $1.5B |
| FY Dec 2023 | $1.3B |
| FY Dec 2022 | $1.0B |
| FY Dec 2020 | n/a |
| Jun 2026 | $386.4M |
| Mar 2026 | $386.4M |
| Dec 2025 | $384.8M |
| Sep 2025 | $345.3M |
| Jun 2025 | $355.8M |
| Mar 2025 | $373.2M |
| Dec 2024 | $370.7M |
| Sep 2024 | $362.1M |
At each fiscal year end
Single quarter
Net margin, TTM
-6.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PIII
| FY Dec 2025 | -10.1% |
| FY Dec 2024 | -9.1% |
| FY Dec 2023 | -4.6% |
| FY Dec 2022 | -25.7% |
| FY Dec 2020 | n/a |
| Jun 2026 | +1.9% |
| Mar 2026 | +0.3% |
| Dec 2025 | -19.6% |
| Sep 2025 | -9.1% |
| Jun 2025 | -5.7% |
| Mar 2025 | -5.5% |
| Dec 2024 | -15.8% |
| Sep 2024 | -12.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$130.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PIII
| FY Dec 2025 | -$91.2M |
| FY Dec 2024 | -$110.1M |
| FY Dec 2023 | -$77.9M |
| FY Dec 2022 | -$128.3M |
| FY Dec 2020 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$57.2M |
| Sep 2024 | -$22.6M |
At each fiscal year end
Single quarter
Debt to equity
1.64x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity PIII
| FY Dec 2025 | n/a |
| FY Dec 2024 | 2.42x |
| FY Dec 2023 | 0.76x |
| FY Dec 2022 | 16.13x |
| FY Dec 2020 | 2,002.20x |
| Jun 2026 | 1.64x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | 4.09x |
| Mar 2025 | 2.71x |
| Dec 2024 | 2.42x |
| Sep 2024 | 1.11x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.09x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt PIII
| FY Dec 2025 | -0.33x |
| FY Dec 2024 | -0.60x |
| FY Dec 2023 | -0.70x |
| FY Dec 2022 | -1.33x |
| FY Dec 2020 | n/a |
| Jun 2026 | -1.09x |
| Mar 2026 | -0.27x |
| Dec 2025 | -0.33x |
| Sep 2025 | -0.49x |
| Jun 2025 | -0.71x |
| Mar 2025 | -0.72x |
| Dec 2024 | -0.60x |
| Sep 2024 | -0.52x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-167.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PIII
| FY Dec 2025 | n/a |
| FY Dec 2024 | -124.6% |
| FY Dec 2023 | -78.1% |
| FY Dec 2022 | -193.4% |
| FY Dec 2020 | n/a |
| Jun 2026 | -167.3% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -257.4% |
| Jun 2025 | -138.2% |
| Mar 2025 | -131.2% |
| Dec 2024 | -124.6% |
| Sep 2024 | -66.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-14.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PIII
| FY Dec 2025 | -20.5% |
| FY Dec 2024 | -16.5% |
| FY Dec 2023 | -6.6% |
| FY Dec 2022 | -16.7% |
| FY Dec 2020 | n/a |
| Jun 2026 | -14.2% |
| Mar 2026 | -17.3% |
| Dec 2025 | -20.5% |
| Sep 2025 | -17.3% |
| Jun 2025 | -18.0% |
| Mar 2025 | -16.8% |
| Dec 2024 | -16.5% |
| Sep 2024 | -11.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital PIII
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2020 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-60.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PIII
| FY Dec 2025 | -135.7% |
| FY Dec 2024 | -75.6% |
| FY Dec 2023 | -28.1% |
| FY Dec 2022 | -111.5% |
| FY Dec 2020 | n/a |
| Jun 2026 | -60.4% |
| Mar 2026 | -105.3% |
| Dec 2025 | -135.7% |
| Sep 2025 | -74.2% |
| Jun 2025 | -82.8% |
| Mar 2025 | -78.8% |
| Dec 2024 | -75.6% |
| Sep 2024 | -46.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PIII
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2020 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value PIII
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2020 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield PIII
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2020 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PIII
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2020 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.5B | $1.5B | $1.3B | $1.0B |
| Operating income | -$270.3M | -$320.7M | -$167.9M | -$1.6B |
| Net income | -$147.9M | -$135.8M | -$57.8M | -$270.1M |
| EPS (diluted) | -45.26 | -54.06 | -0.63 | -6.50 |
| Operating cash flow | -$91.2M | -$110.1M | -$76.0M | -$126.0M |
| Cash | $25.0M | $38.8M | $36.3M | $17.5M |
| Long-term debt | $228.4M | $108.9M | $108.3M | $94.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
PIII Stock Sonar score 6/7 axes
Find similar shapesComparePIII ranks highest on risk and compliance (65th percentile) and insider conviction (27th), and lowest on institutional and government (10th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PIII filings, in plain words
Are P3 Health Partners insiders buying or selling PIII?
In the 180 days to 2026-10-28, P3 Health Partners insiders were net sellers, a net $823.9K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, P3 Health Partners insiders were net sellers of PIII, a net $823.9K across purchases and sales reported on Form 4 by 1 seller. Most of that figure, $823.9K, came from a holder of 10% or more rather than an officer or director. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
